Poly(ADP-ribose) polymerase (PARP) inhibitors should be considered a treatment option for patients with uterine leiomyosarcomas harboring BRCA2 deep deletions, researchers advised. PARP inhibitors are ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led ...

HSP90 buffers certain BRCA1 mutations, allowing them to persist in humans and promote resistance to PARP inhibitor treatments Low-dose HSP90 inhibition restored PARP inhibitor sensitivity in ...

Researchers at The Institute of Cancer Research, London, have increased our understanding of how a cancer drug called a PARP inhibitor stops working in women with breast cancer that has spread. This ...

The use of PARP inhibitors for the treatment of patients with BRCA1/2 mutations represents a milestone in genomically-directed therapies. Olaparib and talazoparib have shown to significantly extend ...

Inherited mutations in the gene BRCA2 significantly increase the risk of carriers to breast and ovarian cancers. BRCA2, a crucial player in the body's DNA repair system, aids in repairing damaged DNA.

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...

Personalized Medicine. 2015;12(2):139-154. Compared to AstraZeneca, the other pharmaceutical companies have fewer Phase III trials running for their compounds. However, the approaches within these ...

Mutations in the BRCA1 gene that are either inherited (germline) or acquired (somatic) might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its ...